Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cridanimod - Pharmsynthez/Xenetic Biosciences

Drug Profile

Cridanimod - Pharmsynthez/Xenetic Biosciences

Alternative Names: Sodium cridanimod; Virexxa; XBIO-101

Latest Information Update: 20 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmsynthez
  • Developer AS Kevelt; Pharmsynthez; Xenetic Biosciences
  • Class Acetic acids; Acridines; Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Interferon stimulants; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Endometrial cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer; Endometrial cancer

Most Recent Events

  • 14 Jun 2022 Xenetic Biosciences terminates phase II trial (due to a change in development strategy ) for Endometrial Cancer (Combination therapy; Second line therapy or greater) in USA (NCT03077698)
  • 17 Jul 2020 Xenetic Biosciences completes phase II trial for Endometrial Cancer (Combination therapy; Second line therapy or greater) in USA (NCT03077698)
  • 31 Dec 2019 Suspended - Phase-II for Endometrial cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Belarus, Slovakia, Ukraine, Czech Republic, USA (IM) before December 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top